PureTech Health
PRTC · Main Market · Health Care · mcap £270m · 111.0p
PureTech founds and part-owns biotech companies, developing some programmes itself before spinning them into separate 'Founded Entities' funded by outside investors. It earns returns through equity stakes, milestones and royalties.
| Target | Promise | Said | Status |
|---|---|---|---|
| 2024 | |||
| 31 Dec 2024 | Initiate two neuroscience clinical trials, LYT-300 and LYT-310, in 2024 | 20 Dec 2023 | … In progress |
|
Result
Not yet due. |
|||
| Today · 11 Oct 2026 | |||
| 2026 | |||
| 31 Dec 2026 | Vedanta Phase 3 RESTORATiVE303 topline data in 2026 | 28 Aug 2024 | … In progress |
|
Also stated 27 Jan 2025
Status so far
Not yet due. |
|||
| 2027 | |||
| 30 Jun 2027 | Seaport BUOY-1 Phase 2b GlyphAllo topline data by H1 2027 | 28 Aug 2024 | … In progress |
|
Status so far
Not yet due. |
|||
| 2028 | |||
| 31 Dec 2028 | Start GlyphAgo Phase 2b/Phase 2/3 anxiety trial by H1 2027; topline by end-2028 | 9 Jun 2026 | … In progress |
|
Status so far
Not yet due. |
|||